作者：
Charlotte,Rypens [1]
;
François,Bertucci [2]
;
Pascal,Finetti [3]
;
Fredika,Robertson [4]
;
Sandra V,Fernandez [3]
;
Naoto,Ueno [5]
;
Wendy A,Woodward [6]
;
Kenneth,Van Golen [7]
;
Peter,Vermeulen [8]
;
Luc,Dirix [9]
;
Patrice,Viens [10]
;
Daniel,Birnbaum [11]
;
Gayathri R,Devi [10]
;
Massimo,Cristofanilli [11]
;
Steven,Van Laere [4]
作者单位：
Translational Cancer Research Unit, GZA Hospitals Sint-Augustinus, Antwerp, Belgium. rypens.charlotte@hotmail.com.
[1]
Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Marseille, France. rypens.charlotte@hotmail.com.
[2]
Predictive Oncology laboratory, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Aix-Marseille Université, Marseille, France.
[3]
Department of Medical Oncology, CRCM, Institut Paoli-Calmettes, Marseille, France.
[4]
University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
[5]
Fox Chase Cancer Center, Philadelphia, PA, USA.
[6]
MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
[7]
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
[8]
Biological Sciences, University of Delaware, Newark, DE, USA.
[9]
Translational Cancer Research Unit, GZA Hospitals Sint-Augustinus, Antwerp, Belgium.
[10]
Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Marseille, France.
[11]
Department of Surgery, Division of Surgical Sciences, Duke University School of Medicine, Durham, NC, USA.
[12]
Duke Consortium for Inflammatory Breast Cancer, Duke Cancer Institute, Durham, NC, UK.
[13]
Department of Medicine, Division of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
[14]
DOI
10.1038/s41523-021-00379-6
PMID
35042871
发布时间
2023-04-17
换一批
换一批
